Muscle Glucose Metabolism in Chronic Obstructive Pulmonary Disease Patients

Sancho-Muñoz, Antonio; Trampal, Carlos; Pascual, Sergi; Martínez‐Llorens, Juana; Chalela, Roberto; Gea, Joaquim; Orozco-Levi, Mauricio

doi:10.1016/j.arbr.2014.04.003

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar situation has been shown in patients with COPD, manifested by the marked acceleration of endogenous glucose flux and clearance, in particular via increases of glycolysis and glucose oxidation [89]. Meanwhile, abnormal glucose metabolism was also detected in the respiratory muscles of COPD patients: the rate of glucose metabolism in the diaphragm was significantly higher than that in other peripheral muscles [90]; Ferguson et al believed that it is correlated with the mechanical loads confronted [91]. The carbohydrate metabolic abnormality may be related to many factors.…”

Section: Chemerin Involved In Glucose and Lipidsupporting

confidence: 62%

Chemerin: A Potential Regulator of Inflammation and Metabolism for Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) features chronic inflammatory reactions of both intra- and extrapulmonary nature. Moreover, COPD is associated with abnormal glucose and lipid metabolism in patients, which influences the prognosis and chronicity of this disease. Abnormal glucose and lipid metabolism are also closely related to inflammation processes. Further insights into the interactions of inflammation and glucose and lipid metabolism might therefore inspire novel therapeutic interventions to promote lung rehabilitation. Chemerin, as a recently discovered adipokine, has been shown to play a role in inflammatory response and glucose and lipid metabolism in many diseases (including COPD). Chemerin recruits inflammatory cells to sites of inflammation during the early stages of COPD, leading to endothelial barrier dysfunction, early vascular remodeling, and angiogenesis. Moreover, it supports the recruitment of antigen-presenting cells that guide immune cells as part of the body’s inflammatory responses. Chemerin also regulates metabolism via activation of its cognate receptors. Glucose homeostasis is affected via effects on insulin secretion and sensitivity, and lipid metabolism is changed by increased transformation of preadipocytes to mature adipocytes through chemerin-binding receptors. Controlling chemerin signaling may be a promising approach to improve various aspects of COPD-related dysfunction. Importantly, several studies indicate that chemerin expression in vivo is influenced by exercise. Although available evidence is still limited, therapeutic alterations of chemerin activity may be a promising target of therapeutic approaches aimed at the rehabilitation of COPD patients based on exercises. In conclusion, chemerin plays an essential role in COPD, especially in the inflammatory responses and metabolism, and has a potential to become a target for, and a biomarker of, curative mechanisms underlying exercise-mediated lung rehabilitation.

show abstract

Section: Chemerin Involved In Glucose and Lipidsupporting

confidence: 62%

Chemerin: A Potential Regulator of Inflammation and Metabolism for Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Twelve studies already included numerical individual data for 721 SUV measurements. Numerical unpublished individual data from published papers [50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66] were obtained through contacting corresponding authors in 17 studies for 21,122 SUV measurements. Therefore, finally a total of 29 studies provided individual patient data and were included in meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements

Eskian

Alavi

Khorasanizadeh

et al. 2018

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Objectives To evaluate the effect of pre-scan blood glucose levels (BGL) on standardized uptake value (SUV) in 18 F-FDG-PET scan. Methods A literature review was performed in the MEDLINE, Embase, and Cochrane library databases. Multivariate regression analysis was performed on individual datum to investigate the correlation of BGL with SUV max and SUV mean adjusting for sex, age, body mass index (BMI), diabetes mellitus diagnosis, 18 F-FDG injected dose, and time interval. The ANOVA test was done to evaluate differences in SUV max or SUV mean among five different BGL groups (< 110, 110-125, 125-150, 150-200, and > 200 mg/dl). Results Individual data for a total of 20,807 SUV max and SUV mean measurements from 29 studies with 8380 patients was included in the analysis. Increased BGL is significantly correlated with decreased SUV max and SUV mean in brain (p < 0.001, p < 0.001,) and muscle (p < 0.001, p < 0.001) and increased SUV max and SUV mean in liver (p = 0.001, p = 0004) and blood pool (p = 0.008, p < 0.001). No significant correlation was found between BGL and SUV max or SUV mean in tumors. In the ANOVA test, all hyperglycemic groups had significantly lower SUVs compared with the euglycemic group in brain and muscle, and significantly higher SUVs in liver and blood pool. However, in tumors only the hyperglycemic group with BGL of > 200 mg/dl had significantly lower SUV max. Conclusion If BGL is lower than 200 mg/dl no interventions are needed for lowering BGL, unless the liver is the organ of interest. Future studies are needed to evaluate sensitivity and specificity of FDG-PET scan in diagnosis of malignant lesions in hyperglycemia.

show abstract

“…A detailed analysis of the echographic findings may also be useful in the early diagnosis of muscle fatigue (64,65). Moreover, some imaging techniques may even allow for an approximation to the metabolic status of the respiratory muscles in both COPD patients and healthy individuals (66,67).…”

Section: Imagingmentioning

confidence: 99%

Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction

et al. 2016

Self Cite

View full text Add to dashboard Cite

Muscle dysfunction is frequently observed in chronic obstructive pulmonary disease (COPD) patients, contributing to their exercise limitation and a worsening prognosis. The main factor leading to limb muscle dysfunction is deconditioning, whereas respiratory muscle dysfunction is mostly the result of pulmonary hyperinflation. However, both limb and respiratory muscles are also influenced by other negative factors, including smoking, systemic inflammation, nutritional abnormalities, exacerbations and some drugs. Limb muscle weakness is generally diagnosed through voluntary isometric maneuvers such as handgrip or quadriceps muscle contraction (dynamometry); while respiratory muscle loss of strength is usually recognized through a decrease in maximal static pressures measured at the mouth. Both types of measurements have validated reference values. Respiratory muscle strength can also be evaluated determining esophageal, gastric and transdiaphragmatic maximal pressures although there is a lack of widely accepted reference equations. Non-volitional maneuvers, obtained through electrical or magnetic stimulation, can be employed in patients unable to cooperate. Muscle endurance can also be assessed, generally using repeated submaximal maneuvers until exhaustion, but no validated reference values are available yet. The treatment of muscle dysfunction is multidimensional and includes improvement in lifestyle habits (smoking abstinence, healthy diet and a good level of physical activity, preferably outside), nutritional measures (diet supplements and occasionally, anabolic drugs), and different modalities of general and muscle training.

show abstract

Muscle Glucose Metabolism in Chronic Obstructive Pulmonary Disease Patients

Cited by 6 publications

References 37 publications

Chemerin: A Potential Regulator of Inflammation and Metabolism for Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation

Chemerin: A Potential Regulator of Inflammation and Metabolism for Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation

Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements

Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction

Contact Info

Product

Resources

About